title: Sarcoidosis mimicking metastatic gynaecological malignancies: a diagnostic and therapeutic challenge?
abstract: Several case reports describing the coexistence of sarcoidosis and malignancy have been published. Therefore, sarcoidosis should always be considered as a differential diagnosis when a cancer patient develops lymphadenopathy. Positron-emission tomography (PET) 2-[18F]-fluoro-2-deoxy-d-glucose (FDG) combined with computed tomography (CT) is widely used for cancer staging and surveillance because it permits localization of metabolically active malignant tissue. PET/CT or CT findings in patients with suspected cancer recurrence can be used to guide early and aggressive therapy. However, benign hypermetabolic lymphadenopathy can mimic malignant lymphadenopathy, both on a conventional CT scan and on PET/CT. Thus, it is important to obtain a histological diagnosis before initiating antineoplastic therapy based on imaging findings. Four cases of patients affected by gynaecological malignancies and coexisting sarcoidosis are reported in this study. Furthermore, the clinical relevance of making a differential diagnosis between gynaecological cancer recurrence and granulomatous disorder is given specific mention.
authors.affiliation: Department of Nuclear Medicine, San Raffaele Scientific Institute, Milan, Italy. mapelli.paola@gmail.com
authors.forename: P
authors.initials: P
authors.lastname: Mapelli
authors.forename: G
authors.initials: G
authors.lastname: Mangili
authors.forename: M
authors.initials: M
authors.lastname: Picchio
authors.forename: E
authors.initials: E
authors.lastname: Rabaiotti
authors.forename: L
authors.initials: L
authors.lastname: Gianolli
authors.forename: C
authors.initials: C
authors.lastname: Messa
authors.forename: M
authors.initials: M
authors.lastname: Candiani
mesh_terms: D000230:Adenocarcinoma / Q000150:complications / Q000000981:diagnostic imaging / Q000556:secondary* / Q000628:therapy; D018262:Adenocarcinoma, Clear Cell / Q000150:complications / Q000000981:diagnostic imaging / Q000556:secondary* / Q000628:therapy; D000328:Adult; D018196:Carcinoma, Adenosquamous / Q000150:complications / Q000000981:diagnostic imaging* / Q000556:secondary* / Q000628:therapy; D018269:Carcinoma, Endometrioid / Q000150:complications / Q000000981:diagnostic imaging / Q000556:secondary* / Q000628:therapy; D003131:Combined Modality Therapy; D003937:Diagnosis, Differential; D016889:Endometrial Neoplasms / Q000150:complications / Q000473:pathology / Q000628:therapy; D005260:Female; D005462:Fluorine Radioisotopes; D019788:Fluorodeoxyglucose F18; D006101:Granuloma, Giant Cell / Q000000981:diagnostic imaging / Q000209:etiology; D006801:Humans; D007223:Infant; D008171:Lung Diseases / Q000150:complications / Q000000981:diagnostic imaging* / Q000188:drug therapy; D008175:Lung Neoplasms / Q000150:complications / Q000000981:diagnostic imaging / Q000556:secondary*; D008198:Lymph Nodes / Q000000981:diagnostic imaging; D008875:Middle Aged; D064847:Multimodal Imaging; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000150:complications / Q000473:pathology / Q000628:therapy; D049268:Positron-Emission Tomography; D019275:Radiopharmaceuticals; D012507:Sarcoidosis / Q000150:complications / Q000000981:diagnostic imaging* / Q000188:drug therapy; D014057:Tomography, X-Ray Computed; D002583:Uterine Cervical Neoplasms / Q000150:complications / Q000473:pathology / Q000628:therapy
chemical_list: D005462:Fluorine Radioisotopes; D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18